Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3882 Adjuvant therapy for pancreatic neuroendocrine tumors – Expert consensus and recommendations for future research

Introduction: With the increase of incidentally diagnosed pancreatic neuroendocrine tumors (panNEN), more patients are treated with curative intent. Survival in patients with a panNEN is impacted by the development of recurrence, but postoperative adjuvant therapy is not yet recommended in guidelines due to absence of evidence. Multiple clinicopathological characteristics have been described in literature to identify patients at high-risk of recurrence who might benefit from adjuvant treatment. Since panNEN are rare tumors, prospective randomized controlled studies on the role of adjuvant therapy in these patients have not been performed.

Conference:

Presenting Author: Heidsma C

Authors: Heidsma C, Engelsman A, Klümpen H, Falconi M, Frilling A,

Keywords: pancreatic neuroendocrine tumor, recurrence, adjuvant therapy, prevention, expert consensus, future research,

#3333 A prospective randomized, double-blind phase 2 study to evaluate the diagnostic efficacy of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: Compared with 68Ga-DOTATATE

Introduction: 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 are somatostatin receptor subtype 2 specific antagonists used for PET/CT imaging.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Zhu W, Jia R, Cheng Y, Zhao H, Bai C,

Keywords: somatostatin receptor antagonist, 68Ga-NODAGA-LM3, 68Ga-DOTA-LM3, 68Ga-DOTATATE, neuroendocrine tumor,

#3332 A prospective randomized, double-blind study to evaluate the safety, biodistribution, and dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors

Introduction: 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 are somatostatin receptor subtype 2 specific antagonists used for PET/CT imaging.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Zhu W, Cheng Y, Jia R, Zhao H, Bai C,

Keywords: somatostatin receptor antagonist, 68Ga-NODAGA-LM3, 68Ga-DOTA-LM3, neuroendocrine tumor,

#1868 Study Protocol: Prospective, Randomized Controlled Trial on the Effect of Primary Resection in Advanced Metastatic NEN of Pancreas and Midgut (PRESNENAS)

Introduction: The role of Primary Tumor resection in advanced metastatic NEN is discussed controversely.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Begum N

Authors: Begum N, Pavel M, Goretzki P, Vonthein R,

Keywords: Prospective Randomized, Controlled Trial, Surgery, Role of Primary Resection,